Full-Time
Sales Executive
Life Sciences, Regulatory and Safety Technology Solutions
IQVIA
10,001+ employees
Analytics and research for life sciences
No salary listed
London, UK + 7 more
More locations: Paris, France | Madrid, Spain | Milan, Metropolitan City of Milan, Italy | Reading, UK | Frankfurt, Germany | Dublin, Ireland | Sant Cugat del Vallès, Barcelona, Spain
Remote
Candidates can be considered in all European locations.
| 🤝Sales & Account Management (1) |
|---|
- Must demonstrate a sustained successful track record selling enterprise solutions (i.e. products, consulting services, hosting and managed services) to Pharmaceutical, Biotech, Medical Device, and/or Clinical Research Organizations
- Demonstrated track record of success working with senior level management in a fast-paced growth environment is essential
- Full sales cycle experience is required: Prospect, Identify Opportunities, Propose Solutions (writing proposals), Negotiate, Close
- Strong written and verbal English skills, quality-oriented proposal writing and proposal management experience
- Ambitious, driven, and self-motivated personality adaptable to a fast-paced high volume and high velocity sales organization
- Bachelor’s degree or equivalent experience required
- Willing to travel as needed throughout EMEA area
- Develop new business by prospecting accounts focusing on Safety and Regulatory products, consulting services, hosting, and managed services.
- Meet or exceed annual quotas by identifying and developing new accounts, following up on existing leads, and generating both incremental and repeatable business
- Develop and maintain productive relationships with key target accounts
- Work collaboratively with the Product Teams, Professional Services Organization, Hosting and Managed Services to ensure a complete and successful delivery of software and service solutions and adapt current solutions, to create new & improved client centric offerings
- Identify and respond to customer needs to define potential opportunities for Regulatory/Pharmacovigilance solutions and propose appropriate tailored solution in line with client needs
- Manage assigned strategic and key account relationships individually or in coordination with Global and Regional Sales Teams
- Possess an understanding of the pharmacovigilance process for both pre-marketed and post-marketed stages of a product
- Selling drug safety and regulatory consulting services, hosting, managed services, and products
- Experience working with Heads of Safety and Regulatory Departments, Chief Medical Officers, and Heads of R&D IT
- Background in Software as a Service (SaaS) market
- 10+ years of experience of working in a Sales, business development or similar position
IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main product, IQVIA Connected Intelligence™, utilizes big data and technology to offer insights that help clients speed up the development and marketing of new medical treatments. This system connects various healthcare data points to provide a comprehensive view of patient needs and treatment effectiveness. Unlike many competitors, IQVIA places a strong emphasis on patient privacy, using advanced technologies to protect individual data. The company's goal is to enhance healthcare outcomes by supporting biotech, pharmaceutical, and medical device companies, as well as researchers and government agencies, in their efforts to understand diseases and improve treatment options.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Simplify's Take
What believers are saying
- IQVIA leads in decentralized clinical trial technologies, enhancing market position.
- The Med-R1 8B LLM launch boosts clinical data interpretation capabilities.
- Recognition for patient engagement app highlights digital health tool importance.
What critics are saying
- Healthcare industry's profit-driven model scrutiny may increase regulatory pressures.
- Access disparities in CAR T-cell therapy could hinder market penetration.
- Reliance on senior notes for financing exposes IQVIA to financial risks.
What makes IQVIA unique
- IQVIA's Connected Intelligence™ offers unique insights across healthcare sectors.
- The company excels in patient privacy with advanced privacy-enhancing technologies.
- IQVIA's Med-R1 8B LLM outperforms larger models in medical reasoning.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Company News
IQVIA wins the Fierce CRO Award for Innovative Approaches to Patient-Centric Research.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in...
<p> <strong>RESEARCH TRIANGLE PARK, N.C.</strong> – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the “Notes”). </p> <p> The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. </p> <p> This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum. </p> <br /> <h5> About IQVIA </h5> <p> IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. </p> <p> IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. </p> <br /> <h5> Forward Looking Statements </h5> <p> Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially. </p> <br /> <h5> IQVIAFIN </h5> <p> Kerri Joseph, IQVIA Investor Relations (<a href="mailto:[email protected]">[email protected]</a>)<br /> +1.973-541-3558 </p>
Research Triangle Park, N.C., - June 16, 2025 - IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program.
New National Campaign Confronts the Healthcare Industry's Perverse Incentives and Sparks a Movement for Preventive WellnessNEW YORK, May 19, 2025 /PRNewswire/ -- Vimergy, the premium supplement company helping people reclaim their health with pure, potent, and timeless products, today launched the "Mouth of America" – an immersive national campaign debuting a large-scale art installation in New York City. Designed to provoke and inspire, the campaign calls attention to America's real health crisis: chronic, system-driven illness fueled by a healthcare model that profits when we stay sick. This problem shows no sign of abating: In 2024, Americans collectively took 215 billion doses of prescription medication